Metoprolol succinate CR/XL (Betaloc ZOK) for cardiovascular diseases: social and economical problems, clinical and clinico-economical studies results
The article presents the review of studies of metoprolol succinate CR/XL (Betaloc ZOK) efficacy and cost-effectiveness for cardiovascular diseases. The β-adrenoblocker metoprolol is an evidence-based alternative for arterial hypertension, heart failure and ischemic heart disease treatment; its efficacy was proved in large randomized clinical trials (MAPHY, MERIT-HF, Goteborg Metoprolol Trial, Stockholm Metoprolol Trial). Prevention of cardiovascular complications and decrease of death rate in patients with chronic heart failure as well as antiatherogenic activity were demonstrated only for metoprolol succinate CR/XL (Betaloc ZOK). A foreign modeling pharmacoeconomical study showed that metoprolol is more cost-effective option for chronic heart failure than bisoprolol and carvedilol. Also a domestic study demonstrated that cost of life-year gained is lower for metoprolol succinate than carvedilol (Dilatrend). Cost of one death averted for metoprolol is lower than for carvedilol and similar to bisoprolol.